1. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. (December 2017) Authors: Tu, Hai-Yan; Ke, E-E; Yang, Jin-Ji; Sun, Yue-Li; Yan, Hong-Hong; Zheng, Ming-Ying; Bai, Xiao-Yan; Wang, Zhen; Su, Jian; Chen, Zhi-Hong; Zhang, Xu-Chao; Dong, Zhong-Yi; Wu, Si-Pei; Jiang, Ben-Yuan; Chen, Hua-Jun; Wang, Bin-Chao; Xu, Chong-Rui; Zhou, Qing; Mei, Ping; Luo, Dong-Lan Journal: Lung cancer Issue: Volume 114(2017) Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. (May 2019) Authors: Yin, Kai; Li, Yang-Si; Zheng, Mei-Mei; Jiang, Ben-Yuan; Li, Wen-Feng; Yang, Jin-Ji; Tu, Hai-Yan; Zhou, Qing; Zhong, Wen-Zhao; Yang, Xue-Ning; Chen, Hua-Jun; Yan, Hong-Hong; Li, Lin-Lin; Wu, Yi-Long; Zhang, Xu-Chao Journal: Lung cancer Issue: Volume 131(2019) Page Start: 134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. (January 2023) Authors: Zhang, Chan-Yuan; Sun, Hao; Su, Jun-Wei; Chen, Yu-Qing; Zhang, Shi-Ling; Zheng, Ming-Ying; Li, Yu-Fa; Huang, Jie; Zhang, Chao; Tai, Zai-Xian; Cai, Miao; Zhang, Xu-Chao; Su, Jian; Xu, Chong-Rui; Yan, Hong-Hong; Chen, Hua-Jun; Wu, Yi-Long; Yang, Jin-Ji Journal: Lung cancer Issue: Volume 175(2023) Page Start: 68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). (March 2019) Authors: Wang, Zhen; Huang, Cheng; Yang, Jin-Ji; Song, Yong; Cheng, Ying; Chen, Gong-Yan; Yan, Hong-Hong; Ben, Xiao-Song; Wang, Bin-Chao; Xu, Chong-Rui; Jiang, Ben-Yuan; Zhou, Qing; Chen, Hua-Jun; Wu, Yi-Long Journal: European journal of cancer Issue: Volume 109(2019) Page Start: 183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. BRAIN study: it is hard to draw a conclusion – Authors' reply. Issue 11 (November 2017) Authors: Yang, Jin-Ji; Yan, Hong-Hong; Wu, Yi-Long Journal: Lancet Issue: Volume 5:Issue 11(2017) Page Start: e34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud. Issue 1 (30th June 2020) Authors: Bai, Xue; Wu, De-Hua; Ma, Si-Cong; Wang, Jian; Tang, Xin-Ran; Kang, Shuai; Fu, Qiang John; Cao, Chuan-Hui; Luo, He-San; Chen, Yu-Han; Zhu, Hong-Bo; Yan, Hong-Hong; Wu, Yi-Long; Dong, Zhong-Yi Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study. Issue 1 (30th June 2020) Authors: Bai, Xue; Wu, De-Hua; Ma, Si-Cong; Wang, Jian; Tang, Xin-Ran; Kang, Shuai; Fu, Qiang John; Cao, Chuan-Hui; Luo, He-San; Chen, Yu-Han; Zhu, Hong-Bo; Yan, Hong-Hong; Wu, Yi-Long; Dong, Zhong-Yi Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. Issue 7 (1st March 2021) Authors: Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Wei, Yu-Cheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Sheng-Xiang; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu Journal: Journal of clinical oncology Issue: Volume 39:Issue 7(2021) Page Start: 713 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Issue 1 (January 2018) Authors: Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Issue 1 (January 2018) Authors: Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗